Podcasts

In part two of this podcast series, Adam Kittai, MD, hematologist and assistant professor of medicine, Ohio State University, highlights findings from the CAPTIVATE study regarding the efficacy of ibrutinib vs placebo for disease-free...

In part one of this podcast series, Adam Kittai, MD, hematologist and assistant professor of medicine, Ohio State University, provides an overview of current research being conducted on chronic lymphocytic leukemia and discusses the results...

Martin Edelman, MD, chair, Department of Hematology/Oncology, deputy director of clinical research, Fox Chase Cancer Center, discusses the disease burden of non-small cell lung cancer, as well as the findings from a phase 3 trial that...

Saad Usmani, MD, MBA, FACP, chief of myeloma service, Memorial Sloan Kettering Cancer Center, discusses current challenges in treating multiple myeloma, financial burdens associated with this type of cancer, and where the future of care may...

Ed Pezalla, MD, MPH, chief executive officer, Enlightenment Bioconsult, LLC, offers insight on the disease burden and costs associated with systemic lupus erythematosus, as well as how payers can support patients seeking testing and treatment.

Gil Melmed, MD, gastroenterologist, Cedars Sinai, Los Angeles, provides insight on fecal microbiota transplantation, including its cost-effectiveness, limitations, and use in treating gastrointestinal diseases such as Clostridioides difficile.

Nasser Altorki, MD, chief of thoracic surgery, New York Presbyterian-Weill Cornell Medicine, discusses the findings from the IMpower010 study, in which adjuvant atezolizumab resulted in a disease-free survival benefit that was superior to...

Norm Smith, former president, Viewpoint Consulting, reflects on a project where his company was once asked to look at reimbursement models linked with C difficile vaccines in countries outside of the United States, and highlights why this is...

Ajai Chari, MD, professor of medicine, hematology, and medical oncology, Mount Sinai, discusses the unmet need in multiple myeloma (MM), challenges specific to treating this disease, why MM is becoming one of the most costly cancers to treat,...